The White House on Friday announced new deals with nine major drugmakers, finalizing an end-of-year push by President Donald Trump to make good on his

Galapagos is flush with billions in cash, but it’s not moving forward with its own pipeline. So what’s the Belgian biotech going to do with

BioMarin plans to dish out $4.8 billion to acquire Amicus Therapeutics and its two approved rare disease medicines, the California biotech said Friday. By gaining

Sens. Bernie Sanders (I-VT) and Markwayne Mullin (R-OK) are not seeing eye to eye on why the Senate failed to pass legislation reauthorizing the FDA’s

Plus, news on: EpimAb, Boehringer and Nxera, Syneron, Amphix Altimmune goes to Phase 3 in MASH: The drug developer’s Phase 2 trial of pemvidutide, a